Life Sciences Research for Lifelong Health

Andrew Kidger

Originally from Sheffield, Andrew completed a BSc honours degree in Biology at the University of Bath, graduating in 2012. His interest in mitogen activated protein (MAP) kinase signalling was stimulated by a research project he undertook during his BSc to develop a system to characterise the binding partners of ERK2 with Dr Jim Caunt.
 
Following this Andrew moved North of the border to complete his PhD with Professor Stephen Keyse at the University of Dundee studying the regulation of MAP kinase signalling by MAP kinase phosphatases (MKPs/DUSPs). His project investigated the role of the ERK1/2-specific phosphatases DUSP5 & DUSP6 in modulating the development of mutant RAS-driven cancers.
 
Andrew is now continuing his interest in ERK signalling in the Cook lab, where he is investigating the functional consequences of the differences in mechanisms of action of a range of published ERK inhibitors.
 

Latest Publications

Control of cell death and mitochondrial fission by ERK1/2 MAP Kinase signalling.

Cook SJ, Stuart K, Gilley R

The FEBS journal
1742-4658: (2017)

PMID: 28548464

Visualisation of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe.

Sipthorp J, Lebraud H, Gilley R

Bioconjugate chemistry
1520-4812: (2017)

PMID: 28449575

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.

Galloway A, Saveliev A, Łukasiak S

Science (New York, N.Y.)
352 1095-9203:453-9 (2016)

PMID: 27102483

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ

Cell cycle (Georgetown, Tex.)
15 1551-4005:506-18 (2016)

PMID: 26959608